[go: up one dir, main page]

HRP20110133T1 - Novi derivati 3-fenilpropanske kiseline kao aktivatori ppar-tipa receptora, postupak njihovog dobivanja i njihova upotreba u kozmetičkim ili farmaceutskim pripravcima - Google Patents

Novi derivati 3-fenilpropanske kiseline kao aktivatori ppar-tipa receptora, postupak njihovog dobivanja i njihova upotreba u kozmetičkim ili farmaceutskim pripravcima Download PDF

Info

Publication number
HRP20110133T1
HRP20110133T1 HR20110133T HRP20110133T HRP20110133T1 HR P20110133 T1 HRP20110133 T1 HR P20110133T1 HR 20110133 T HR20110133 T HR 20110133T HR P20110133 T HRP20110133 T HR P20110133T HR P20110133 T1 HRP20110133 T1 HR P20110133T1
Authority
HR
Croatia
Prior art keywords
radical
propyl
phenyl
propanoic acid
methoxyphenyl
Prior art date
Application number
HR20110133T
Other languages
English (en)
Inventor
Boiteau Jean-Guy
Clary Laurence
Pascal Jean-Claude
Parnet V�ronique
Original Assignee
Galderma Research & Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research & Development filed Critical Galderma Research & Development
Publication of HRP20110133T1 publication Critical patent/HRP20110133T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/55—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/71—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/31—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/32—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/31—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/35—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Spoj, naznačen time što ima opću formulu (I) niže: u kojoj:- R1 predstavlja hidroksilni radikal ili alkoksi radikal;- R2 predstavlja vodik, alkilni radikal, cikloalkilni radikal, izborno supstituirani aralkilni radikal ili polieterski radikal;- R3 predstavlja vodik, halogen, alkilni radikal ili alkoksi radikal;- R4 predstavlja alkilni radikal, izborno supstituirani arilni radikal ili izborno supstituirani aralkilni radikal;- X predstavlja atom kisika ili radikal CH2;- Y predstavlja atom kisika, radikal NR5 ili radikal OSO2, OCO, NR5CO ili NR5SO2;- R5 predstavlja atom vodika ili alkilni radikal; a također i njegove soli s farmaceutski prihvatljivom kiselinom ili bazom, njihovi farmaceutski prihvatljivi solvati i njihovi hidrati. Patent sadrži još 22 patentna zahtjeva.

Claims (23)

1. Spoj, naznačen time što ima opću formulu (I) niže: [image] u kojoj: – R1 predstavlja hidroksilni radikal ili alkoksi radikal; – R2 predstavlja vodik, alkilni radikal, cikloalkilni radikal, izborno supstituirani aralkilni radikal ili polieterski radikal; – R3 predstavlja vodik, halogen, alkilni radikal ili alkoksi radikal; – R4 predstavlja alkilni radikal, izborno supstituirani arilni radikal ili izborno supstituirani aralkilni radikal; – X predstavlja atom kisika ili radikal CH2; – Y predstavlja atom kisika, radikal NR5 ili radikal OSO2, OCO, NR5CO ili NR5SO2; – R5 predstavlja atom vodika ili alkilni radikal; a također i njegove soli s farmaceutski prihvatljivom kiselinom ili bazom, njihovi farmaceutski prihvatljivi solvati i njihovi hidrati.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je u obliku soli s alkalnim ili zemnoalkalnim metalom ili soli s organskim aminom.
3. Spoj u skladu s patentnim zahtjevom 1, naznačen time što, kada nosi aminsku funkcionalnu skupinu, je u obliku soli s mineralnom ili organskom kiselinom.
4. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što navedeni alkilni radikal predstavlja nerazgranati ili razgranati zasićeni ugljikovodični lanac koji sadrži 1 do 12 atoma ugljika.
5. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni alkilni radikal se bira između metilnog, etilnog, propilnog, izopropilnog, butila, izobutilnog, tert-butilnog, pentilnog, izoamilnog, amilnog i heksilnog radikala.
6. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni cikloalkilni radikal predstavlja zasićeni prstenasti ugljikovodični lanac koji sadrži 3 do 7 atoma ugljika.
7. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni izborno supstituirani arilni radikal se bira između fenila i naftila, izborno supstituiranih s jednim ili više atoma ili atomskih skupina, koje se bira između alkila, alkoksi, halogena, hidroksila, cijano, trifluormetila i nitro.
8. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni izborno supstituirani aralkilni radikal se bira između benzila i fenetila, izborno supstituiranih s jednim ili više atoma ili atomskih skupina, koje se bira između alkila, alkoksi, halogena, hidroksila, cijano, trifluormetila i nitro.
9. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni atom halogena se bira između atoma fluora, klora, broma i joda.
10. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni alkoksi radikal se bira između metoksi, etoksi, izopropiloksi, n-propiloksi, tert-butoksi, n-butoksi, n-pentiloksi i n-heksiloksi radikala.
11. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni polieterski radikal se bira između radikala koji sadrže 1 do 7 atoma ugljika, prekinutih najmanje jednim atomom kisika, po mogućnosti metoksietoksi, etoksietoksi, metoksietil, etoksietil i metoksietoksietoksi radikala.
12. Spoj u skladu s patentnim zahtjevom 1, naznačen time što ga se bira iz skupine koju čine: 1. 3-{4-[3-(4-benziloksi-3-metoksifenil)propil]-3-butoksifenil}propanska kiselina 2. 3-{3-butoksi-4-[3-(4-etoksi-3-metoksifenil)propil]fenil}propanska kiselina 3. 3-{3-butoksi-4-[3-(4-butoksi-3-metoksifenil)propil]fenil}propanska kiselina 4. 3-{3-butoksi-4-[3-(4-metansulfoniloksi-3-metoksifenil)propil]fenil}propanska kiselina 5. 3-(4-{3-[4-(butan-1-sulfoniloksi)-3-metoksifenil]propil}-3-butoksifenil)propanska kiselina 6. 3-{3-butoksi-4-[3-(4-etansulfoniloksi-3-metoksifenil)propil]fenil)propanska kiselina 7. 3-[4-{3-[4-(butan-1-sulfoniloksi)-3-metoksifenil]propil}-3-(3-fluorbenziloksi)fenil]propanska kiselina 8. 3-[4-{3-[4-(butan-1-sulfoniloksi)-3-metoksifenil]propil}-3-(4-fluorbenziloksi)fenil]propanska kiselina 9. 3-(4-{3-[4-(butan-1-sulfoniloksi)-3-metoksifenil]propil}-3-ciklopropilmetoksifenil)propanska kiselina 10. 3-[4-{3-[4-(butan-1-sulfoniloksi)-3-metoksifenil]propil}-2-(3-metoksibenziloksi)fenil]propanska kiselina 11. 3-(4-{3-[4-(butan-1-sulfoniloksi)-3-metoksifenil]propil}-2-butoksifenil)propanska kiselina 12. metil-3-[4-[3-(4-acetilaminofenil)propil]-3-(2-metoksietoksi)fenil]propanoat 13. metil-3-(4-{3-[4-(acetilmetilamino)fenil]propil}-3-metoksifenil)propanoat 14. 3-(4-{3-[4-(butan-1-sulfoniloksi)fenil]propil}-3-hidroksifenil)propanska kiselina 15. 3-(4-{3-[4-(butan-1-sulfonilamino)fenil]propil}-3-butoksifenil)propanska kiselina 16. 3-[4-(2-{4-[(3-klorobenzoil)metilamino]fenil}etoksi)-3-(2-etoksietoksi)fenil]propanska kiselina 17. 3-[3-butoksi-4-(2-{4-[metil-(2-p-toliletansulfonil)amino]fenil}etoksi)fenil]propanska kiselina 18. 3-(4-{3-[4-(butan-1-sulfoniloksi)-3-metoksifenil]propil}-3-butoksifenil)propanska kiselina 19. metil-3-{3-butoksi-4-[3-(4-etoksi-3-fluorfenil)propil]fenil}propanoat 20. 3-[4-{3-[4-(butan-1-sulfoniloksi)-2-metoksifenil]propil}-3-(2-etoksietoksi)fenil]propanska kiselina 21. 3-(4-{3-[3-kloro-4-(heksan-1-sulfoniloksi)fenil]propil}-3-etoksifenil)propanska kiselina 22. 3-{4-[2-(3-kloro-4-etoksifenil)etoksi]-3-metoksifenil}propanska kiselina 23. 4-{3-[4-(2-karboksietil)-2-metoksifenil]propil}fenil-butirat.
13. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačen time što ima najmanje jednu od sljedećih karakteristika: – R1 je hidroksilni radikal, – R2 predstavlja alkilni radikal ili polieterski radikal, – R3 predstavlja atom vodika, alkoksi radikal ili halogen, – R4 predstavlja alkilni radikal, – X predstavlja atom kisika ili skupinu CH2, – Y predstavlja skupinu -NR5SO2 ili skupinu -OSO2, gdje R5 je atom vodika ili alkilni radikal.
14. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačen time što ima najmanje jednu od sljedećih karakteristika: – R1 je hidroksilni radikal, – R2 predstavlja niži alkilni radikal, – R3 predstavlja niži alkoksi radikal, – R4 predstavlja niži alkilni radikal, – X predstavlja atom kisika ili skupinu CH2, – Y predstavlja skupinu -OSO2.
15. Kozmetički pripravak, naznačen time što sadrži, u fiziološki prihvatljivoj podlozi, najmanje jedan od spojeva u skladu s bilo kojim od patentnih zahtjeva 1 do 14.
16. Pripravak u skladu s patentnim zahtjevom 15, naznačen time što koncentracija jednog ili više spojeva u skladu s bilo kojim od patentnih zahtjeva 1 do 14 je između 0,001 % i 3 %, težinski, u odnosu na ukupnu težinu pripravka.
17. Kozmetička upotreba pripravka u skladu s bilo kojim od patentnih zahtjeva 1 do 14 ili pripravka u skladu s bilo kojim od patentnih zahtjeva 15 i 16, naznačena time što navedeni pripravak je namijenjen higijeni tijela ili kose.
18. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 14, naznačen time što ga se upotrebljava kao medikament.
19. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 14, naznačena time što je navedeni spoj namijenjen proizvodnji pripravka za reguliranje i/ili obnavljanje metabolizma lipida u koži.
20. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 14, naznačena time što je navedeni spoj namijenjen proizvodnji pripravka za liječenje: – dermatoloških poremećaja, povezanih s poremećajem keratinizacije, povezanim sa staničnom diferencijacijom i proliferacijom, osobito za liječenje običnih akni, komedonskih akni, polimorfnih akni, akni rozacea, nodulocističnih akni, acne conglobata, staračkih akni i sekundarih akni, poput solarnih akni, akni povezanih s lijekovima ili profesionalnih akni; – ihtioze, ihtioziformnih stanja, Darierove bolesti, palmoplantarne keratoderme, leukoplakije i leukoplakiformnih stanja, i kutani ili mucous (buccal) lichen; – dermatoloških poremećaja s upalnom imunoalergijskom komponentom, uz ili bez poremećaja stanične proliferacije, osobito kutane, mukozne ili psorijaze noktiju, psorijatičnog reumatizma, kutane atopije, poput ekzema, respiratorne atopija ili hipertrofije desni; – dermalnih ili epidermalnih proliferacija, bilo dobroćudnih ili zloćudnih, te bilo virusnog podrijetla ili ne, osobito običnih bradavica, pljosnatih bradavica i veruciformne epidermodispalzije, oralne ili papilomatoze floride, limfoma T-stanica; – proliferacija koje mogu biti inducirane ultraljubičastim zračenjem, osobito epitelioma bazalnih i spinalnih stanica; – prekanceroznih lezija kože, osobito keratoakantoma; – imunosnih dermatoza, osobito eritematoznog lupusa; – imunosnih buloznih bolesti; – kolagenskih bolesti, osobito skleroderme; – dermatoloških ili općih poremećaja s imunološkom komponentom; – poremećaja kože uzrokovanih izlaganjem UV zračenju, fotoinduciranog ili kronološkog starenja kože, aktiničnih pigmentacija i keratoze, ili bilo koje patologije povezane s kronološkim ili aktiničnim starenjem, osobito kseroze; – poremećaja funkcije lojnih žlijezda, osobito hiperseboreje s aknama ili obične seboreje; – poremećaja cikatrizacije ili strija; – poremećaja pigmentacije, poput hiperpigmentacije, melazme, hipopigmentacije ili vitiliga; – poremećaja metabolizma lipida, poput pretilosti, hiperlipidemije, ili dijabetesa neovisnog o inzulinu; – upalnih poremećaja, poput artritisa; – kanceroznih ili prekanceroznih stanja; – alopecije različitog podrijetla, osobito alopecije uzrokovane kemoterapijom ili zračenjem; – poremećaja imunosnog sustava, poput astme, dijabetesa tip I, multiple skleroze ili drugih selektivnih disfunkcija imunosnog sustava; i – poremećaja kardiovaskularnog sustava, poput arterioskleroze ili hipertenzije.
21. Farmaceutski pripravak, naznačen time što sadrži, u fiziološki prihvatljivom mediju, najmanje jedan spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 14.
22. Pripravak u skladu s patentnim zahtjevom 21, naznačen time što koncentracija jednog ili više spojeva u skladu s bilo kojim od patentnih zahtjeva 1 do 14 je između 0,001 % i 10 %, težinski, u odnosu na ukupnu težinu pripravka.
23. Pripravak u skladu s patentnim zahtjevom 21, naznačen time što koncentracija jednog ili više spojeva u skladu s bilo kojim od patentnih zahtjeva 1 do 14 je između 0,01 % i 1 %, težinski, u odnosu na ukupnu težinu pripravka.
HR20110133T 2007-06-05 2008-06-04 Novi derivati 3-fenilpropanske kiseline kao aktivatori ppar-tipa receptora, postupak njihovog dobivanja i njihova upotreba u kozmetičkim ili farmaceutskim pripravcima HRP20110133T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0755476A FR2917084B1 (fr) 2007-06-05 2007-06-05 Nouveaux derives d'acide 3-phenyl propanoique activateurs des recpteurs de type ppar, leur methode de preparation et leur utilisation dans des compositions cosmetiques ou pharmaceutiques.
PCT/FR2008/050996 WO2008152333A2 (fr) 2007-06-05 2008-06-04 Nouveaux dérivés d'acide 3-phényl propanoïque activateurs des récepteurs de type ppar, leur méthode de préparation et leur utilisation dans des compositions cosmétiques ou pharmaceutiques

Publications (1)

Publication Number Publication Date
HRP20110133T1 true HRP20110133T1 (hr) 2011-04-30

Family

ID=38800781

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110133T HRP20110133T1 (hr) 2007-06-05 2008-06-04 Novi derivati 3-fenilpropanske kiseline kao aktivatori ppar-tipa receptora, postupak njihovog dobivanja i njihova upotreba u kozmetičkim ili farmaceutskim pripravcima

Country Status (21)

Country Link
US (1) US7879907B2 (hr)
EP (1) EP2155662B1 (hr)
JP (1) JP2010529098A (hr)
KR (1) KR20100028548A (hr)
CN (1) CN101679216A (hr)
AR (1) AR068974A1 (hr)
AT (1) ATE490234T1 (hr)
AU (1) AU2008263668A1 (hr)
CA (1) CA2688239A1 (hr)
CY (1) CY1111495T1 (hr)
DE (1) DE602008003800D1 (hr)
DK (1) DK2155662T3 (hr)
ES (1) ES2357183T3 (hr)
FR (1) FR2917084B1 (hr)
HR (1) HRP20110133T1 (hr)
MX (1) MX2009012841A (hr)
PL (1) PL2155662T3 (hr)
PT (1) PT2155662E (hr)
RU (1) RU2009148335A (hr)
SI (1) SI2155662T1 (hr)
WO (1) WO2008152333A2 (hr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461183B2 (en) 2008-05-26 2013-06-11 Genfit PPAR agonist compounds, preparation and uses
FR2984730A1 (fr) * 2011-12-22 2013-06-28 Diverchim Nouvelles compositions cosmetiques anti-age et depigmentantes
CN103965048B (zh) * 2014-05-06 2016-02-17 西北农林科技大学 反式肉桂酸酯类化合物及其合成方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2653119B1 (fr) * 1989-10-18 1994-08-05 Lipha Nouveaux aryloxy alcoyl benzenes, leurs procedes de preparation et les compositions pharmaceutiques en renfermant.
WO1999011255A1 (fr) * 1997-08-28 1999-03-11 Ono Pharmaceutical Co., Ltd. Regulateurs du recepteur active par les agents de proliferation des peroxysomes
MA26634A1 (fr) * 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9904421D0 (sv) * 1999-12-03 1999-12-03 Astra Ab New compounds
FR2812876B1 (fr) * 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
CN101284773A (zh) * 2001-08-09 2008-10-15 小野药品工业株式会社 羧酸衍生物及以它为活性成分的药剂
FR2833949B1 (fr) * 2001-12-21 2005-08-05 Galderma Res & Dev NOUVEAUX LIGANDS ACTIVATEURS DES RECEPTEURS PPARy, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION EN MEDECINE HUMAINE AINSI QU'EN COSMETIQUE
JP4594611B2 (ja) * 2002-11-08 2010-12-08 武田薬品工業株式会社 受容体機能調節剤
BRPI0407506A (pt) * 2003-02-13 2006-02-14 Wellstat Therapeutics Corp compostos para o tratamento de distúrbios metabólicos, seu uso e composição farmacêutica compreendendo os mesmos
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
MXPA06001739A (es) * 2003-08-14 2006-05-12 Asahi Kasei Pharma Corp Derivado de acido arilalcanoico substituido y uso del mismo.
US20060257987A1 (en) * 2003-08-20 2006-11-16 Gonzalez Valcarcel Isabel Cris Ppar modulators
JPWO2006057448A1 (ja) * 2004-11-26 2008-06-05 武田薬品工業株式会社 アリールアルカン酸誘導体
AU2006287521A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. PPARactive compounds
FR2892412B1 (fr) * 2005-10-26 2008-05-16 Galderma Res & Dev Composes biaromatiques modulateurs des ppars
JP5243696B2 (ja) * 2006-03-17 2013-07-24 田辺三菱製薬株式会社 ベンゼン誘導体
FR2902789A1 (fr) * 2006-06-21 2007-12-28 Genfit Sa Derives de 1,3-diphenylpropane substitues, preparations et utilisations

Also Published As

Publication number Publication date
WO2008152333A3 (fr) 2009-02-19
FR2917084A1 (fr) 2008-12-12
WO2008152333A9 (fr) 2009-12-10
PL2155662T3 (pl) 2011-04-29
PT2155662E (pt) 2011-01-27
WO2008152333A2 (fr) 2008-12-18
EP2155662A2 (fr) 2010-02-24
DK2155662T3 (da) 2011-02-21
AR068974A1 (es) 2009-12-23
EP2155662B1 (fr) 2010-12-01
CA2688239A1 (fr) 2008-12-18
ATE490234T1 (de) 2010-12-15
DE602008003800D1 (de) 2011-01-13
SI2155662T1 (sl) 2011-04-29
MX2009012841A (es) 2009-12-11
US7879907B2 (en) 2011-02-01
FR2917084B1 (fr) 2009-07-17
ES2357183T3 (es) 2011-04-19
CY1111495T1 (el) 2015-08-05
US20100158843A1 (en) 2010-06-24
AU2008263668A1 (en) 2008-12-18
CN101679216A (zh) 2010-03-24
JP2010529098A (ja) 2010-08-26
KR20100028548A (ko) 2010-03-12
RU2009148335A (ru) 2011-07-20

Similar Documents

Publication Publication Date Title
RU2003106424A (ru) БИФЕНИЛЬНЫЕ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ АКТИВАТОРОВ РЕЦЕПТОРОВ PPARγ
ATE488490T1 (de) Tripentylcitrate und deren verwendung als weichmacher
ATE123754T1 (de) Phenylethenylverbindungen mit retenoidähnlicher wirkung.
JP5355089B2 (ja) Ｐｐａｒを調節する二芳香族化合物
ATE185558T1 (de) Prostaglandin-synthase hemmer
ATE509935T1 (de) Mischungen aus mono-carboxylfunktionalisierten dialkylphosphinsäuren, ein verfahren zu ihrer herstellung und ihre verwendung
ES2187025T3 (es) Nuevos agentes quelantes de hierro (iii) activos via oral.
HRP20110133T1 (hr) Novi derivati 3-fenilpropanske kiseline kao aktivatori ppar-tipa receptora, postupak njihovog dobivanja i njihova upotreba u kozmetičkim ili farmaceutskim pripravcima
RU2009149610A (ru) Новые производные 3-фенилакриловой кислоты в качестве активаторов рецепторов типа ppar, способ их получения и их применение в косметических или фармацевтических композициях
RU2007109778A (ru) Новые биароматические соединения, которые активируют рецепторы типа ppar, и их применение в косметических и фармацевтических композициях
ES431307A1 (es) Procedimiento para la preparacion de nuevos derivados de quinoleina.
NO943701L (no) Kortikoid-17,21-dikarboksylsyreester samt kortikosteroid-17-karboksylsyreester-21-karbonsyreester, fremgangsmåte for fremstilling derav og legemiddel inneholdende disse
US3988229A (en) Stabilized photopolymerizable polymeric compositions containing a photoinitiator and a nitrone derivative
PT1831149E (pt) Novos ligandos que modulam recetores rar e sua utilização em medicina humana e em cosmética
RS50929B (sr) Novi postupak za industrijsku sintezu metildiestra 5-amino-3-karboksimetil-4-cijano-2-tiofenkarboksilne kiseline i primena dvovalentnih soli ranelinske kiseline i njenih hidrata u pomenutoj sintezi
RU2004138294A (ru) Новые лиганды, являющиеся ингибититорами рецепторов rar, способ их получения и их применение для лечения человека и в лечебной косметике
RU2007109780A (ru) Новые биароматические соединения, которые активируют рецепторы типа ppar, и их применение в космических или фармацевтических композициях
RU2005119990A (ru) Новые биароматические соединения, являющиеся активаторами рецепторов типа ppar гамма и их применение в косметических или фармацевтических композициях
ES437530A1 (es) Procedimiento para la obtencion de nuevos derivados de acido13-tiaprostanico.
YU48685B (sh) Aldehidni postupak za dobijanje sumpornih derivata imidazola i novi intermedijeri
SE7909367L (sv) Sett att framstella piperidyl-indol-derivat, ny framstelld forening och dess salter samt anvendning derav sasom lekemedel och farmaceutiska kompositioner innehallande dessa foreningar
CA2097824A1 (en) Functionalized vinyl azoles and their use
ES2285554T3 (es) Nuevos compuestos que son moduladores de receptores de tipo ppar y su uso en composiciones cosmeticas o farmaceuticas.
CA2484450A1 (en) Ligands that are inhibitors of the rar receptors
RU2006143054A (ru) Новые биароматические соединения, которые активируют рецепторы ppary-типа, способы их получения и их применение в косметике или в фармацевтических композициях